MacroGenics Inc (MGNX)
Healthcare
Biotechnology
3.70 $
-2.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns MacroGenics Inc (MGNX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 82.5% of the shares are freely tradable; institutional investors hold 70.3%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
70.3%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.4%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
82.5%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
64Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.46 | 6,012,000 | -4.9 | 03/31/2026 |
| Vanguard Group Inc | 6.65 | 4,226,941 | +0.1 | 12/31/2025 |
| Renaissance Technologies Corp | 4.66 | 2,963,559 | +1.9 | 03/31/2026 |
| Millennium Management LLC | 4.40 | 2,794,357 | +41.5 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.18 | 2,653,853 | +0.0 | 03/31/2026 |
| Acadian Asset Management LLC | 4.00 | 2,544,000 | +199,116.9 | 03/31/2026 |
| Two Sigma Investments LLC | 3.98 | 2,527,829 | +152.9 | 03/31/2026 |
| Bank of America Corp | 3.78 | 2,401,814 | +30.7 | 03/31/2026 |
| Marshall Wace Asset Management Ltd | 3.19 | 2,025,526 | +57.7 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BB Biotech AG Ord | 15.61 | 9,919,992 | +0.0 | 09/30/2025 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.